Date: August 21, 2012 By:
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine. The grants were awarded under the Innovation for HIV Vaccine Discovery (IHVD) initiative, which is expected to receive up to $34.8 million over the next four years.
“Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development,” said NIAID Director Anthony S. Fauci, M.D. “These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection.”
Ragon Institute Investigator Dr. Galit Alter was one of 14 recipients of this NIAID grant.
View full list of awardees (via NIAID)
The lab of the Ragon Institute faculty member Hernandez Moura Silva, PhD, recently published a review in Science Immunology regarding resident tissue macrophages (RTMs), shedding light on their multifaceted roles in organ health.
After three years off due to the COVID-19 pandemic, the Ragon-MIT course HST.434 returned this January to provide 24 students a once in a lifetime learning experience
Ragon core member and MIT associate professor of chemical engineering Brandon DeKosky, PhD, was one of five MIT faculty members recently awarded $25 million to take on Cancer Grand Challenges.